Healthcare

Senate Bill 136 primarily eliminates the requirement for healthcare providers to notify patients about dense breast tissue after mammography. This change directly impacts patients undergoing mammograms and the medical facilities that perform these screenings in Michigan. The bill also enacts broader amendments concerning the use of radiation machines for mammography procedures. These modifications are made by amending and repealing specific sections within the existing Public Health Code.

SB 95 (the "hospital price transparency act") prohibits hospitals from attempting to collect debts for services provided when they were not complying with state price transparency laws. It specifically bans hospitals from using debt collectors, suing patients, or reporting debts to credit bureaus for care received during non-compliance periods. The bill directly affects hospitals that fail to publicly list prices for services (like "chargemaster" rates) and patients who received care during those violations. Key provisions define "collection actions" and clarify that hospitals cannot pursue payment for non-compliant billing periods, offering patients remedies if hospitals attempt collection anyway.

SB 483 creates a palliative care advisory task force within Michigan's health department. The task force will study current palliative care services and make recommendations to improve access and quality for patients facing serious illness. This affects Michigan's healthcare system by establishing a new body to address gaps in end-of-life care services.

SB 405 amends Michigan's "Administration of Opioid Antagonists Act" by revising the definition of "governmental agency" to explicitly exclude school district boards, public school academies, and licensed healthcare providers (under Public Health Code Part 209). This change means these entities will no longer be subject to the act's requirements regarding opioid antagonist access and training. The bill directly affects school districts, public school academies, and licensed healthcare facilities by removing them from the scope of the law. The amendment clarifies which organizations must comply with the act's provisions, focusing on state and local government entities rather than schools or healthcare providers. This is a technical definitional update with no new requirements or funding changes.

SB 94 prohibits drug manufacturers, wholesalers, and distributors from restricting 340B program pharmacies from accessing or receiving 340B drugs, which are discounted medications for safety-net healthcare providers. It requires 340B entities (like community health centers) to submit annual compliance reports starting in 2026, including program audits and community impact details. Additionally, drug manufacturers must report price increases exceeding 15% for drugs costing over $40 per treatment course, including cost data and patent details. These provisions directly affect pharmaceutical companies, participating pharmacies, and healthcare providers enrolled in the federal 340B drug pricing program.